Cold tablet (over the counter medicine) effects on driving performance and safety.
Conditions
Interventions
Intervention group: The current study is a double-blind, randomized, crossover clinical trial. Random allocation will be performed using block randomization with fixed block sizes (two 12-trial blocks
such that participants will receive two tablets in each of the three driving stages, and these two tablets will be in the form of: a) two placebo tablets, b) one cold tablet and one placebo tablet, an
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Individuals aged 20 to 60 years Having valid driver's license and a driving record of at least 6 months on various routes within and outside the city. Having no chronic or acute illness affecting driving performance and safety Not taking sedative medication and foods, hypnotic, and stimulants (such as sedative-hypnotics, sedative herbal medicines, significant caffeine, etc.) a few days before the test Getting enough sleep the night before the test Volunteering of an individual to participate in the study
Exclusion criteria
Exclusion criteria: individual's mismatch with the testing environment (such as the driving simulator) The volunteer's Inability to continue participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standard Deviation of Lateral Position (SDLP). Timepoint: About two hours after the intervention (administration of the drug or placebo) and during the driving simulator test. Method of measurement: Software and sensors embedded in the Sahand-1 driving simulator system.;Standard Deviation of Speed (SDS). Timepoint: About two hours after the intervention (administration of the drug or placebo) and during the driving simulator test. Method of measurement: Software and sensors embedded in the Sahand-1 driving simulator system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reaction Time (RT). Timepoint: About two hours after the intervention (administration of the drug or placebo) and during the driving simulator test. Method of measurement: Software and sensors embedded in the Sahand-1 driving simulator system.;Lane Departure. Timepoint: About two hours after the intervention (administration of the drug or placebo) and during the driving simulator test. Method of measurement: Software and sensors embedded in the Sahand-1 driving simulator system.;Reaching a Specific Speed. Timepoint: About two hours after the intervention (administration of the drug or placebo) and during the driving simulator test. Method of measurement: Software and sensors embedded in the Sahand-1 driving simulator system. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Hossein Abolghasemi Fakhri
Tabriz University of Medical Sciences
Outcome results
None listed